CFO departs Intercept as trickle becomes mass exodus from NASH biotech
Intercept’s leadership has now been almost entirely hollowed out and turned over. On Wednesday, the once highly-valued biotech announced that its CFO, Sandip Kapadia, is leaving the company to “pursue another opportunity.”
Kapadia joins a major exodus at a company that, less than a year ago, believed it was on its way to a first-of-its-kind approval in a blockbuster indication and traded accordingly. But the FDA rebuffed that application for the common liver-scarring disease NASH last June and in the months since, their founding CEO Mark Pruzanski handed over the reins and their CMO, Jason Campagna, left to be a CMO of a much smaller upstart.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.